Implantable defibrillators lead to decrease in cardiac arrests
- Researchers estimate that implantable cardioverter defibrillators (ICDs) account for a third of the decrease in cardiac arrests caused by ventricular fibrillation (VF).
- The incidence of VF-related cardiac arrest dropped significantly between 1995 and 2008.
- In greater Amsterdam, ICDs prevented 81 cardiac arrests between 2005 and 2008.
EMBARGOED UNTIL 3 pm CT/4 pm ET, Monday, August 6, 2012
DALLAS, August 6, 2012 — Implantable cardioverter defibrillators account for one-third of the decrease in cardiac arrests caused by ventricular fibrillation in North-Holland, according to research in Circulation, an American Heart Association journal.
VF is an abnormal heart rhythm that makes the heart quiver so it can’t pump blood.
ICDs are small electronic devices implanted in the chest that detect potentially fatal abnormal heart rhythms and try to stop them with electric shocks. Generally, only people with a high risk of sudden cardiac death — mostly those at high risk of abnormal heartbeats and survivors of a previous cardiac arrest — receive ICDs.
Previous studies have shown a gradual 15-year decrease in VF-related cardiac arrests suffered outside the hospital setting — from 54 percent to 38 percent in the United States and Europe. However, the incidence of such cardiac arrests from other abnormal heart rhythms continues to increase each year.
Researchers estimated that ICDs prevented 81 cardiac arrests during the 2005-2008 study. To reach this estimate, they multiplied the number of life-threatening abnormal heart rhythms stopped by an ICD by the probability that the rhythm would have led to a call to emergency medical services (EMS) and a resuscitation attempt.
They assumed that a life-threatening abnormal heart rhythm would prompt calls to EMS in 62 percent of cases, and an attempt at resuscitation would occur in 67 percent of those people.
“At least one in 20 ICD carriers can expect a life-saving shock from their device each year,” said Rudolph W. Koster, M.D., Ph.D., senior author and associate professor of cardiology at the Academic Medical Center in Amsterdam, The Netherlands.
Researchers used data from the Amsterdam Resuscitation Studies registry of cardiac resuscitations by EMS in the greater Amsterdam area in 1995-1997, and all EMS cardiac arrest interventions in the area in 2005-2008.
Focusing on people known to have VF when EMS arrived, researchers found:
- An estimated 339 shocks successfully stopped 194 instances of life-threatening abnormal heart rhythms in 166 people.
- The percentage of patients with VF cardiac arrest fell from 63 percent in 1995-1997 to 47 percent in 2005-2008.
- The annual incidence of VF cardiac arrests fell significantly, from 21.1 people per 100,000 to 17.4 people per 100,000.
- Incidence of cardiac arrests related to other abnormal rhythms increased significantly, from 12.2 per 100,000 to 19.4 per 100,000 annually.
It’s unknown what caused the other two-thirds of decline in VF arrests or why cardiac arrests vs. other abnormal heart rhythms have increased.
“The possible mechanisms are only guesses without much solid evidence,” Koster said.
It’s likely that western countries that implant ICDs for similar indications would see a similar reduction in out-of-hospital cardiac arrest from ventricular fibrillation, he said.
Co-author are: Michiel Hulleman, M.Sc.; Jocelyn Berdowski, Ph.D.; Joris R. de Groot, M.D., Ph.D.; Pascal F.H.M van Dessel, M.D., Ph.D.; C. Jan Willem Borleffs, M.D., Ph.D.; Marieke T. Blom, M.A.; Abdenasser Bardai, M.D.; Carel C. de Cock, M.D., Ph.D.; Hanno L. Tan, M.D., Ph.D.; Jan G.P. Tijssen, Ph.D. and Rudolph W. Koster, M.D., Ph.D. Author disclosures are on the manuscript.
Although the study received no outside funding, the ARREST database is maintained by an unconditional grant of Physio Control Inc. and a grant from the Netherlands Heart Foundation.
Read the latest guidelinesfor the use of ICDs.
For the latest heart news on Twitter, follow @Heart News. For research updates from the journal Circulation, follow @CircAHA.
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
Addtional resources are available in the right column.
For Media Inquiries: (214) 706-1173
Tagni McRae (214) 706-1383; Tagni.Mcrae@heart.org
Bridgette McNeill: (214) 706-1135; Bridgette.McNeill@heart.org
Julie Del Barto (broadcast): (214) 706-1330; Julie.DelBarto@heart.org
For Public Inquiries: (800) AHA-USA1 (242-8721)